William T. Harris

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

Jane C. Davies, Steve Cunningham, William T. Harris et al. · The Lancet Respiratory Medicine · 2016 · 339 citations · Full text

Single-arm Study, Pathology, Pulmonary Fibrosis +2

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 262 citations · Full text

Medicine, Cftr Gating Mutation, Pediatrics +1

Airway microbiota across age and disease spectrum in cystic fibrosis

Edith T. Zemanick, Brandie D. Wagner, Charles E. Robertson et al. · European Respiratory Journal · 2017 · 216 citations · Full text

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB)

Margaret Rosenfeld, Steve Cunningham, William T. Harris et al. · Journal of Cystic Fibrosis · 2019 · 128 citations · Full text

TGF-Beta Downregulation of Distinct Chloride Channels in Cystic Fibrosis-Affected Epithelia

Hongtao Sun, William T. Harris, Stephanie Kortyka et al. · PLoS ONE · 2014 · 92 citations · Full text